Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Metastatic Triple-Negative Breast Cancer (US/EU)
Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval of the PARP inhibitors Lynparza (AstraZeneca) and Talzenna (Pfizer) and the immune checkpoint inhibitors Tecentriq (Roche / Genentech) (EU only) and Keytruda (Merck & Co.). The approval of the TROP2-targeted antibody-drug conjugate Trodelvy (Immunomedics) has also expanded treatment options. Despite the availability of new therapies, significant clinical and commercial opportunity remains for the development of new therapies to improve patient outcomes. Our Unmet Need module analyzes the key drivers of prescribing and assesses how emerging therapies can capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the most important factors that drive medical oncologists’ prescribing decisions for triple-negative breast cancer?
- How do key current therapies perform on key clinical attributes for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a new therapy for triple-negative breast cancer?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 63 U.S. and 30 European medical oncologists fielded in May 2022.
Key companies: Eisai, Roche / Genentech, Pfizer, AstraZeneca, Merck & Co., Gilead Sciences, Daiichi Sankyo.
Key drugs: Abraxane, Avastin, Halaven, Keytruda, Lynparza, Talzenna, Tecentriq, Trodelvy.
Table of contents
- Breast Cancer - Unmet Need - Detailed, Expanded Analysis: Metastatic Triple-Negative Breast Cancer (US/EU)
- Executive summary
- Unmet need - Metastatic triple-negative breast cancer - executive summary - July 2022
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products/Regimens for triple-negative breast cancer and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed medical oncologists' prescribing decisions in metastatic triple-negative breast cancer
- Importance of efficacy attributes to prescribing decisions in metastatic triple-negative breast cancer: United States
- Importance of efficacy attributes to prescribing decisions in metastatic triple-negative breast cancer: Europe
- Importance of safety and tolerability attributes to prescribing decisions in metastatic triple-negative breast cancer: United States
- Importance of safety and tolerability attributes to prescribing decisions in metastatic triple-negative breast cancer: Europe
- Importance of convenience of administration attributes to prescribing decisions in metastatic triple-negative breast cancer: United States
- Importance of convenience of administration attributes to prescribing decisions in metastatic triple-negative breast cancer: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in metastatic triple-negative breast cancer: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in metastatic triple-negative breast cancer: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for triple-negative breast cancer: United States
- Overall performance of key therapies for triple-negative breast cancer: Europe
- Mean overall performance of key therapies for triple-negative breast cancer: United States and Europe
- Relative performance of key therapies for triple-negative breast cancer across select efficacy attributes: United States
- Relative performance of key therapies for triple-negative breast cancer across select efficacy attributes: Europe
- Relative performance of key therapies for triple-negative breast cancer across select safety and tolerability attributes: United States
- Relative performance of key therapies for triple-negative breast cancer across select safety and tolerability attributes: Europe
- Relative performance of key therapies for triple-negative breast cancer across select convenience of administration attributes: United States
- Relative performance of key therapies for triple-negative breast cancer across select convenience of administration attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in triple-negative breast cancer
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for triple-negative breast cancer on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for triple-negative breast cancer on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in triple-negative breast cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in triple-negative breast cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in triple-negative breast cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in triple-negative breast cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in triple-negative breast cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in triple-negative breast cancer: Europe
- Key findings: unmet need in triple-negative breast cancer and related indications
- Surveyed medical oncologists' ascribed level of unmet need in triple-negative breast cancer and related indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in triple-negative breast cancer and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the triple-negative breast cancer market and emerging therapy insights
- Opportunity: a novel therapy or regimen that extends overall survival
- Opportunity: a novel therapy that improves progression-free survival
- Opportunity: a novel therapy with improved tumor response
- Opportunity: a therapy that improves convenience of administration
- Areas of opportunity in the triple-negative breast cancer market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- First-line metastatic triple-negative breast cancer target product profile: attribute importance
- Median overall survival (months)
- Median progression-free survival (months)
- Objective response rate (% of patients)
- Incidence of grade 3/4 hematological toxicities (% of patients)
- Incidence of grade 3/4 gastrointestinal toxicities (% of patients)
- Incidence of grade 3/4 immune-mediated toxicities (% of patients)
- Price per 28-day cycle
- Conjoint analysis-based simulation of a market scenario
- First-line metastatic triple-negative breast cancer market simulation: share of preference of target product profiles included in the market scenario
- First-line metastatic triple-negative breast cancer market simulation: likelihood to prescribe target product profiles included in the market scenario
- First-line metastatic triple-negative breast cancer market simulation: target product profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive summary
Priyanka Sharma, M.B.A., is an analyst on the Oncology team at Clarivate. Prior to joining this company, she was a knowledge management consultant with ZS Associates, where she was responsible for designing and conducting secondary research on disease markets and providing end-to-end support to pharmaceutical clients during products’ life cycles. She also worked at DelveInsight Business Research, where she conducted pharmaceutical market forecasting in multiple therapy areas for various clients. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmaceutical management from the University Institute of Applied Management Sciences at Panjab University in Chandigarh, India.